Skip to main content
. 2017 Mar 21;8(23):37186–37199. doi: 10.18632/oncotarget.16427

Table 3. Anticoagulant activity of 6a, 6a-b, 6a-e, 6k, 6k-a and 6k-b.

No. FXa Ki (nM) 2 × PT (μM) (Human)
6a 20.5 8.4
6a-b 13.4 4.2
6a-e 39.1 3.8
6k 17.0 16.4
6k-a 58.6 16.9
6k-b 25.4 11.3
rivaroxaban 0.7 0.2